Seattle Genetics, Inc.
) recently commenced a phase I/II study to evaluate Adcetris in
Teva Pharmaceutical Industries Ltd.
) Treanda (bendamustine) for Hodgkin lymphoma (HL) patients after
The single-arm, open-label study is divided into two cohorts.
The phase I cohort's primary endpoint is to find the recommended
dosing level of Treanda in combination with Adcetris and evaluate
the safety and tolerability of this combination.
The complete remission rate will be assessed as the primary
endpoint of the phase II cohort. Secondary endpoints include best
response, duration of response and progression-free survival.
After receiving Adcetris plus Treanda patients will have an
option to suspend the therapy and undergo an autologous stem cell
transplant (ASCT) following which treatment with single-agent
Adcetris will be resumed.
Seattle Genetics also announced that Adcetris data on first
line salvage therapy in relapsed/refractory HL was presented
recently. In this study, 85.7% of the patients showed an
objective response rate.
In May 2013, the US Food and Drug Administration (FDA)
accepted a supplemental biologics license application (sBLA) for
Adcetris for retreatment and extended duration of medication with
the drug beyond 16 cycles in relapsed HL and systemic anaplastic
large cell lymphoma (sALCL).
We note that Adcetris was approved by the FDA in Aug 2011 for
the treatment of patients with HL after failure of ASCT or after
failure of at least two prior multi-agent chemotherapy regimens
in patients who are not suitable for ASCT. Adcetris was also
approved for sALCL in treatment-experienced patients.
Seattle Genetics carries a Zacks Rank #3 (Hold). Right now,
Anika Therapeutics Inc.
Myriad Genetics Inc.
) look more attractive with a Zacks Rank #1 (Strong Buy).
ANIKA THERAPEUT (ANIK): Free Stock Analysis
MYRIAD GENETICS (MYGN): Free Stock Analysis
SEATTLE GENETIC (SGEN): Free Stock Analysis
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.